Aclaris Therapeutics, Inc. (ACRS)
3.31
-0.05
(-1.49%)
USD |
NASDAQ |
Feb 25, 16:00
3.31
0.00 (0.00%)
After-Hours: 16:47
Aclaris Therapeutics Research and Development Expense (Quarterly) : 13.03M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Oramed Pharmaceuticals, Inc. | 1.153M |
| PMV Pharmaceuticals, Inc. | 18.18M |
| Atea Pharmaceuticals, Inc. | 38.35M |
| Instil Bio, Inc. | 9.127M |
| Definium Therapeutics, Inc. | 30.98M |